Every third breath you take in Delhi or Mumbai is polluted. Add to that smoking, biomass fuel smoke, and a booming population of elderly with COPD — and you have a respiratory time bomb. The India respiratory drugs market report by MRFR shows this market is $2.86 billion and will hit $5.60 billion by 2035, growing at 6.3% CAGR. Inhaled corticosteroids (ICS) are the largest drug class, but combination drugs (ICS + LABA) are the fastest‑growing.

What's driving the surge? Air pollution is now a public health emergency. The India respiratory drugs market analysis highlights that COPD is the fastest‑growing disease type, overtaking asthma in many regions. Why? Because chronic exposure to PM2.5 is turning healthy lungs into stiff, inflamed organs. And many patients are diagnosed late — after irreversible damage.

The good news: inhaler technology has improved. Dry powder inhalers (DPIs) are easier to use than pressurized metered‑dose inhalers (pMDIs). And generic versions of Advair and Symbicort are now available in India at 70% lower cost.

The bad news: inhaler adherence is terrible. Most patients stop using their preventer inhaler as soon as they feel better, then end up in the ER. The solution? Smart inhalers with Bluetooth trackers — still niche in India, but growing.